STONY BROOK, NY, November 22, 2022 – The Renaissance School of Medicine at Stony Brook University will be part of a new medical school consortium in the New York metro region to train young scientists in kidney, urology and hematology research – crucial areas in medicine that involve special training and the need for more research, as kidney disease and conditions such as sickle cell disease affect millions and often disproportionally in marginalized groups.
The medical research training initiative, called the New York Consortium for Interdisciplinary Training in Kidney, Urological, and Hematological Research (NYC Train KUHR), is supported by a five-year $6.6 million grant from the National Institutes of Health (NIH). The Renaissance School of Medicine will co-lead this program to provide an opportunity to graduate students and post-doctoral clinical and research fellows for NIH-sponsored research training in these disciplines. Albert Einstein College of Medicine (co-lead and the NIH site contact) will partner with Stony Brook, as well as the Icahn School of Medicine at Mount Sinai and Columbia University Irving Medical Center.
“This new NIH-funded program will provide interdisciplinary research training in hematology, urology and nephrology for predoctoral and postdoctoral fellows at our school of medicine and the other New York institutions,” says Peter Igarashi, MD, a nephrologist and Dean of the Renaissance School of Medicine. “Our selection for this highly competitive award reflects our collective expertise in kidney, blood, and urologic disorders, and our track record of education innovation to our early career scientists.”
NYC Train KUHR will recruit up to 10 trainees each year. The trainees will work under mentors from various institutions, have access to data from current and past studies, and attend routine networking and professional presentations from the applicable medical disciplines.
Sandeep Mallipattu, MD, Chief of the Division of Nephrology and Hypertension Division at Stony Brook, will co-lead the consortium.
“A key priority of NYC Train KUHR is to enrich the diversity of researchers in our fields,” says Dr. Mallipattu, who notes that a major part of this training initiative is to include trainees from groups historically underrepresented in medicine.
For more perspective and details about the consortium, see this press release from Einstein.